Nabriva Therapeutics Plc(OTC) NBRVF

Nabriva Therapeutics plc is a biopharmaceutical company dedicated to developing innovative anti-infective medications aimed at treating serious infections. The company markets SIVEXTRO and XENLETA, with ongoing research into additional applications for XENLETA and the development of CONTEPO.

Products and Services

• SIVEXTRO for acute bacterial skin infections
• XENLETA for community-acquired bacterial pneumonia
• CONTEPO for complicated urinary tract infections in development

Growth Outlook

• Ongoing Phase I trials for XENLETA in various indications
• Potential expansion into pediatric and cystic fibrosis infections
• Focus on addressing unmet needs in anti-infective therapies

Financial Highlights

• Q1 2023 revenue of $7.59 million, showing a steady demand for products
• Net income for Q1 2023 was -$8.7 million, reflecting ongoing investment in R&D
• Cash and cash equivalents at $1.8 million as of March 31, 2023

Nabriva Therapeutics is positioned in the biotechnology sector, focusing on critical areas of healthcare. The company’s marketed products, SIVEXTRO and XENLETA, are designed to address significant medical needs, particularly in the realm of bacterial infections. The ongoing research into additional applications for XENLETA and the development of CONTEPO highlight the company's commitment to innovation and addressing unmet medical needs. The growth outlook remains promising, with ongoing clinical trials that could expand the therapeutic applications of existing products. The financial highlights indicate a focus on growth, with substantial investments in research and development, which may lead to future revenue growth as new products are brought to market. Despite current net losses, the revenue trends suggest a solid foundation for potential future profitability as the company continues to innovate and expand its product offerings.